• Biogen stock is moving in positive territory. Why is BIIB stock advancing?High-Dose Spinraza Regimen Expands Treatment ApproachSpinraza is a prescription medicine that treats spinal muscular atrophy (SMA) in pediatric and adult patients.The high dose regimen of Spinraza, which includes two 50 mg doses given 14 days apart, followed by maintenance doses every four months, is expected to enhance treatment options for patients.The FDA’s approval is based on data from the Phase 2/3 DEVOTE study, which showed ...